MORRIS PLAINS, N.J., Jan. 31, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the issuance of US patent 8,105,596, "Immunotherapy of B-cell malignancies using anti-CD22 antibodies."
